VFA
XERS icon

Voya Financial Advisors’s Xeris Biopharma Holdings XERS Stock Holding History

Voya Financial Advisors’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-39,164
Closed -$165K – 627
2021
Q1 		$165K Buy
+39,164
New +$211K 0.01% 646

Other funds holding XERS

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Voya Financial Advisors's XERS Position: Q2 2021 in Review

Voya Financial Advisors sold out of Xeris Biopharma Holdings (XERS) in Q2 2021, closing a stake of 39,164 shares — an estimated $165K sold.

Voya Financial Advisors first reported a position in XERS in Q1 2021 and held it in 1 quarter. The position peaked at $165K in Q1 2021. 93 funds tracked by Wall St. Rank hold XERS as of Q2 2021.

  • Voya Financial Advisors reported no remaining Xeris Biopharma Holdings position as of Q2 2021 after selling out during the quarter.
  • Voya Financial Advisors sold 39,164 Xeris Biopharma Holdings shares in Q2 2021, an estimated $165K.
  • Voya Financial Advisors first reported a position in Xeris Biopharma Holdings in Q1 2021 and held it in 1 quarter.
  • Voya Financial Advisors's Xeris Biopharma Holdings position peaked at $165K in Q1 2021.
  • 93 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2021.

Based on Voya Financial Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.